- Home
- EIC vs TERN Comparison
EIC vs TERN Comparison
Compare EIC & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- TERN
- Stock Information
- Founded
- EIC N/A
- TERN 2017
- Country
- EIC United States
- TERN United States
- Employees
- EIC N/A
- TERN N/A
- Industry
- EIC Finance/Investors Services
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- EIC Finance
- TERN Health Care
- Exchange
- EIC Nasdaq
- TERN Nasdaq
- Market Cap
- EIC 355.7M
- TERN 310.8M
- IPO Year
- EIC 2019
- TERN 2021
- Fundamental
- Price
- EIC $14.39
- TERN $3.04
- Analyst Decision
- EIC Strong Buy
- TERN Buy
- Analyst Count
- EIC 1
- TERN 5
- Target Price
- EIC $17.50
- TERN $18.38
- AVG Volume (30 Days)
- EIC 180.9K
- TERN 1.0M
- Earning Date
- EIC 05-20-2025
- TERN 05-08-2025
- Dividend Yield
- EIC 16.69%
- TERN N/A
- EPS Growth
- EIC N/A
- TERN N/A
- EPS
- EIC 1.97
- TERN N/A
- Revenue
- EIC $46,223,036.00
- TERN N/A
- Revenue This Year
- EIC $39.61
- TERN N/A
- Revenue Next Year
- EIC $27.28
- TERN N/A
- P/E Ratio
- EIC $7.32
- TERN N/A
- Revenue Growth
- EIC 72.79
- TERN N/A
- 52 Week Low
- EIC $12.73
- TERN $1.87
- 52 Week High
- EIC $16.71
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- EIC 51.50
- TERN 51.89
- Support Level
- EIC $14.27
- TERN $2.93
- Resistance Level
- EIC $14.67
- TERN $3.62
- Average True Range (ATR)
- EIC 0.21
- TERN 0.25
- MACD
- EIC 0.10
- TERN 0.03
- Stochastic Oscillator
- EIC 72.16
- TERN 39.27
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.